Researchers are developing a new vaccine to fight the Zika virus which has the potential to cause the elimination of the disease globally.

Zika is a mosquito-borne flavivirus that can cause microcephaly (birth defects where the baby’s head is smaller than expected) and severe birth defects in infants of infected mothers.

Introduction of an effective new vaccine to fight the Zika virus, vaccine to prevent infection in pregnant women and congenital effects on unborn children.

The team has developed a new Zika vaccine that has proven itself in a mouse model. This is the first vaccine study to show that T cell-based vaccines offer protection against systemic Zika infection.

Our vaccine offers advantages over other vaccines developed and eliminates the ongoing problem of spreading infection after exposure to the dengue virus. This finding shows for the first time that a protective T cell vaccine against Zika is available.

The Zika virus is very dangerous if you are pregnant and there is no therapy or vaccination available. If we can advance this work and immunize the most vulnerable women of childbearing age, we can stop the adverse effects of Zika infection during pregnancy and make a major contribution to the health of the global community.

The next step is to place the vaccine in Phase I readiness in human clinical trials. This includes more preclinical studies that are very important to determine the most effective dose and show protection against Zika infection in various preclinical disease models.

The results of this study will have a significant impact on other studies on the development of flavivirus vaccines and shift the focus of developing vaccines based on virus envelopes and T cell antibodies to vaccines.Scientist